$17.160
+0.752 (+4.38%)收盤時
IKNA 資訊
IKNA 事件
iKena Oncology appoints Yarema as CEO of ImageneBio
Ikena Oncology (IKNA) announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio, of the combined company after the anticipated closing. Dr. Yarema joins the team after most recently serving as President and Chief Executive Officer and as a member of the Board of Directors of Poseida Therapeutics (PSTX)
Ikena announces 1-for-12 reverse stock split, approval of Inmagene merger
Ikena Oncology stockholders voted in favor of all proposals, including a proposal approving the previously announced merger with Inmagene Biopharmaceuticals. The merger proposal allows for the issuance of shares of Ikena's common stock both to the shareholders of Inmagene and to the investors of the financing concurrent to the merger. Following the closing of the merger, the combined company plans to change its name from Ikena Oncology, Inc. to ImageneBio, Inc. and trade on Nasdaq under the ticker symbol (IMA). In addition, the shareholders approved a proposal for a reverse stock split, giving Ikena's board of directors the authority to select a ratio for the split ranging from 1-for-5 to 1-for-15. Ikena announced that it will effect a 1-for-12 reverse stock split of Ikena common stock that is expected to be effective around the end of July, prior to the closing of the merger. The combined company's common stock is expected to begin trading on Nasdaq on a split-adjusted basis around the end of July. The reverse stock split effects all issued and outstanding shares of Ikena common stock. The reverse stock split will reduce the number of shares of issued and outstanding Ikena common stock from approximately 48.2M to approximately 4M.
iKena says ISS, Glass Lewis recommends stockholders vote for merger
Ikena Oncology announced that Institutional Shareholder Services and Glass, Lewis & Co. recommend that stockholders vote FOR the issuance of shares in connection with the previously disclosed proposed merger with Inmagene Biopharmaceuticals at Ikena's upcoming Annual Meeting of Stockholders on July 15, 2025. ISS and Glass Lewis are leading U.S. institutional voting advisory services that regularly publish analyses on public shareholder votes. Inmagene is a privately held, clinical stage biopharmaceutical company focused on developing IMG-007, a nondepleting anti-OX40 monoclonal antibody engineered to have a silenced antibody-dependent cellular cytotoxicity function to minimize potential safety risks, and a prolonged half-life to enable potentially less frequent dosing regimens.
iKena Oncology, Inmagene enter definitive merger agreement, private placement
Ikena Oncology and Inmagene Biopharmaceuticals have entered into a definitive merger agreement. In connection with the merger, Ikena has entered into subscription agreements for a $75 million private placement with a syndicate that includes new investors such as Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors such as BVF Partners, Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed. The combined company will focus on the development of IMG-007, a monoclonal antibody targeting OX40, for the treatment of atopic dermatitis. The combined company plans to operate under the name "ImageneBio" and trade on NASDAQ under the ticker "IMA". OX40 is a costimulatory receptor that presents primarily on activated T cells. Anti-OX40 mAbs have demonstrated efficacy in placebo-controlled studies in atopic dermatitis. IMG-007 is a mAb targeting OX40 with potential utility in a wide range of inflammatory indications, including atopic dermatitis, asthma, hidradenitis suppurativa, systemic sclerosis and others. IMG-007 has a longer half-life compared to other OX40-targeting mAbs in Phase 2 and later development, enabling its potential for dose and schedule optimization. In addition, IMG-007 has silenced antibody dependent cellular cytotoxicity function, and is non-T cell depleting, leading to a potentially improved tolerability profile relative to other mAbs in the class. IMG-007's Phase 2b clinical trial in atopic dermatitis is expected to begin in early 2025. Following the closing of the merger and the Financing, Ikena stockholders are expected to own approximately 34.8% of the combined company. Inmagene equity holders are expected to own approximately 43.5%, and the Financing investors are expected to own approximately 21.7%. The board of directors of the combined company will be comprised of three directors from the current Inmagene board, two directors from the current Ikena board, a board member representing the investors in the Financing, and a new independent board member. Inmagene and Ikena will mutually decide on future leadership of ImageneBio and a formal search for the chief executive officer of the combined company has been initiated. The shareholders of the two companies will obtain contingent value rights. The Inmagene shareholders will receive CVRs for Inmagene's non-IMG-007 assets, and the Ikena shareholders will receive CVRs for Ikena's legacy pipeline assets. The transaction has been approved by the board of directors of both companies and is expected to close in mid-2025, subject to customary closing conditions, including approval by the shareholders of each company. In connection with the reverse merger, directors and officers of both companies, certain shareholders of Inmagene and certain shareholders of Ikena have executed support agreements, pursuant to the terms of which they have agreed to vote all of their shares of capital stock in favor of the merger or the issuance of Ikena shares in the merger, as applicable.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。